CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
  
  OVERVIEW OF ACTIVITY
  The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in numerous clinical trials for patients with lung cancer. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided medical oncologists and patients with many additional and beneficial FDA-endorsed treatment options. To bridge the gap between research and patient care, this video presentation by Dr Matthew Gubens uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of lung cancer with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Appraise the FDA approval of durvalumab consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this agent can be appropriately and safely integrated into routine clinical practice.
  • Recall the results from the recently presented Phase III FLAURA trial evaluating the role of osimertinib versus gefitinib or erlotinib as first-line therapy for patients with NSCLC with an EGFR tumor mutation, and consider how these findings may affect current or future clinical practice.
  • Develop an optimal management approach for patients with NSCLC with an EGFR tumor mutation and CNS metastases, considering the implications of symptomatology, number of lesions and other relevant factors.
  • Review published research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for newly diagnosed metastatic NSCLC, and identify patients appropriate for this strategy outside of a research setting.
  • Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and offer supportive strategies to minimize and manage these toxicities.
  • Describe ongoing trials evaluating novel applications of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, targeted therapy) for diverse lung cancer variants, and counsel appropriately selected patients about participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITIES
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  Matthew Gubens, MD, MS
  Associate Professor, Thoracic Medical Oncology
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Heron Therapeutics Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.
  
  Project Steering Committee Members
  
  Alexander E Drilon, MD
  Clinical Director
  Developmental Therapeutics Clinic
  Associate Attending Physician
  Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene, Blueprint Medicines, Genentech, Helsinn Group, Ignyta Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology, TP Therapeutics Inc.
  
  Nasser H Hanna, MD
  Professor of Medicine
  Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research
  Indiana University
  Indianapolis, Indiana
  
  Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Merck; Data and Safety Monitoring Board/Committee: BeyondSpring Inc, United Therapeutics/Precision for Medicine.
  
  Leora Horn, MD, MSc
  Associate Professor of Medicine
  Ingram Associate Professor of Cancer Research
  Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, Incyte Corporation, Pfizer Inc, Tesaro, A GSK Company, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.
  
  Nathan A Pennell, MD, PhD
  Associate Professor, Hematology and Medical Oncology
  Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  Director, Cleveland Clinic Lung Cancer Medical Oncology Program
  Cleveland, Ohio
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Cota Inc, Lilly, Regeneron Pharmaceuticals Inc.
  
  Suresh S Ramalingam, MD
  Professor of Hematology and Medical Oncology
  Assistant Dean for Cancer Research
  Emory University School of Medicine
  Deputy Director, Winship Cancer Institute
  Atlanta, Georgia
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Lilly, Merck, Novartis.
  
  Lecia V Sequist, MD, MPH
  Associate Professor of Medicine
  Harvard Medical School
  Center for Thoracic Cancers
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Genentech, Merrimack Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Merrimack Pharmaceuticals Inc, Novartis.
  
  Heather Wakelee, MD
  Professor of Medicine
  Division of Oncology
  Stanford University School of Medicine
  Stanford Cancer Institute
  Stanford, California
  
  Advisory Committee: ACEA Biosciences Inc, AstraZeneca Pharmaceuticals LP, Genentech, Novartis, Roche Laboratories Inc; Contracted Research: ACEA Biosciences Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech, Gilead Sciences Inc, MedImmune Inc, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: September 2019
  Expiration date: September 2020